Nucleic acid drugs are promising therapeutic modalities due to their unique ability to target genetic pathways with exquisite specificity . Antisense oligonucleotides (ASOs) lead the charge with over 10 drugs approved in the past two decades 2 . ASOs are short synthetic strands of DNA designed to modulate gene expression by binding to target mRNA through base-pair complementarity. Approved ASO drugs operate through two main mechanisms: the ASO-RNA duplex can either modulate pre-mRNA splicing or trigger RNase H-mediated degradation . However, despite their success, approved ASOs target a narrow spectrum of diseases and their key mechanisms of action are predominantly localised within the nucleus.